Data Challenge: Beat the SuperBugs in SSA

Background and Rationale Healthcare-associated infections (HAIs) present a severe, hidden crisis across sub-Saharan Africa, significantly escalating patient morbidity and mortality. This emergency is driven by extensive antimicrobial resistance (AMR), which threatens to render routine clinical care ineffective in resource-constrained environments. Leveraging dataset resources from the Surveillance Partnership to Improve Data for Action on Antimicrobial Resistance (SPIDAAR), our initiative, Beat the SuperBugs in SSA, seeks to transform robust genomic and clinical surveillance data into actionable, youth-driven public health advocacy. Objectives and Methodology Aligned with the core mission of the Usmanu Danfodiyo University Young Antimicrobial Resistance Stewards (UDUYARS), this project utilizes observational cohort data collected across major health facilities in Kenya, Ghana, Malawi, and Uganda. Our primary objective is to evaluate the clinical and microbiological outcomes of hospitalized patients experiencing HAIs. We focus on estimating resistance rates among priority pathogens, describing treatment outcomes at the end of therapy and hospital discharge, assessing all-cause and infection-related mortality, and analyzing the impact of AMR on hospital length of stay. Key Insights and Impact The SPIDAAR cohort demonstrates a critical 16.7% case fatality rate, with a staggering 80.9% of pathogenic isolates identified as third-generation cephalosporin-resistant or multidrug-resistant. Crucially, inadequate or unknown antimicrobial treatment adequacy, which is frequently caused by drug-resistant phenotypes, nearly triples the odds of mortality (OR 2.90, 95% CI 0.99 to 8.36) for severe manifestations like bloodstream infections and hospital-acquired pneumonia. Beat the SuperBugs in SSA empowers early-career scientists and civil society to bridge the gap between surveillance data and grassroots community action, ultimately driving the implementation of robust infection prevention frameworks and optimized treatment guidelines across the region.